Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR285
MIFTS: 64

Chronic Myelomonocytic Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Chronic Myelomonocytic Leukemia

About this section

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 39 12 77 54 60 30 6 15 17
Leukemia, Myelomonocytic, Chronic 54 74
Leukemia Myelomonocytic Chronic 56
Cmml 60

Characteristics:

Orphanet epidemiological data:

60
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080188
NCIt 51 C3178
ICD10 34 C93.1
MESH via Orphanet 46 D015477
ICD10 via Orphanet 35 C93.1
UMLS via Orphanet 75 C0023480
Orphanet 60 ORPHA98823
UMLS 74 C0023480
Sources

Summaries for Chronic Myelomonocytic Leukemia

About this section
Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to juvenile myelomonocytic leukemia and mastocytosis, and has symptoms including fever, fatigue and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Developmental Biology and Akt Signaling. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming... more...

Sources

Related Diseases for Chronic Myelomonocytic Leukemia

About this section

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 181)
# Related Disease Score Top Affiliating Genes
1 juvenile myelomonocytic leukemia 31.1 CSF2 DNMT3A FLT3 JAK2 NF1 PDGFRB
2 mastocytosis 30.8 KIT PDGFRB TET2
3 chronic neutrophilic leukemia 30.8 ASXL1 CSF3R SETBP1
4 refractory anemia 30.6 ASXL1 JAK2 RUNX1 TET2
5 leukemia, acute lymphoblastic 30.6 ETV6 FLT3 RUNX1
6 systemic mastocytosis 30.2 ASXL1 JAK2 KIT PDGFRB TET2
7 hypereosinophilic syndrome 30.2 CSF2 KIT PDGFRB
8 myelodysplastic myeloproliferative cancer 30.1 ASXL1 CSF2 CSF3R JAK2 NF1 PTPN11
9 atypical chronic myeloid leukemia 30.1 ASXL1 CSF3R JAK2 PDGFRB RUNX1 SETBP1
10 essential thrombocythemia 29.9 ASXL1 EZH2 JAK2 TET2
11 polycythemia vera 29.9 JAK2 KIT PDGFRB TET2
12 acute leukemia 29.8 ETV6 FLT3 JAK2 KIT RUNX1
13 megakaryocytic leukemia 29.8 CSF2 JAK2 RUNX1
14 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.7 CSF1 ETV6 FLT3 KIT RUNX1
15 myelofibrosis 29.6 ASXL1 EZH2 FLT3 JAK2 KIT TET2
16 leukemia 29.5 CSF2 CSF3R ETV6 FLT3 JAK2 KIT
17 myeloma, multiple 29.4 CSF2 JAK2 KIT PTPN11
18 severe congenital neutropenia 29.2 CSF2 CSF3R JAK2 PTPN11
19 myeloproliferative neoplasm 29.1 JAK2 KIT PDGFRB PTPN11 TET2
20 aplastic anemia 29.0 ASXL1 CSF1 CSF2 CSF3R FLT3 GATA2
21 leukemia, chronic myeloid 28.6 CSF2 CSF3R ETV6 FLT3 GATA2 JAK2
22 myeloid leukemia 28.5 CSF2 CSF3R DNMT3A ETV6 FLT3 GATA2
23 myelodysplastic syndrome 28.2 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
24 leukemia, acute myeloid 27.8 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
25 pdgfrb-associated chronic eosinophilic leukemia 12.0
26 primary hypereosinophilic syndrome 10.4 ETV6 PDGFRB
27 b-cell childhood acute lymphoblastic leukemia 10.4 ETV6 RUNX1
28 myeloproliferative disorder, chronic, with eosinophilia 10.4 ETV6 PDGFRB
29 lymphocytic leukemia 10.4
30 adhesions of uterus 10.3 KDM6A PDGFRB
31 hematopoietic stem cell transplantation 10.3
32 thrombocytopenia 10.3
33 lymphoma 10.3
34 leukemia, chronic lymphocytic 2 10.2
35 leukemia, chronic lymphocytic 10.2
36 chromosomal triplication 10.2
37 dendritic cell tumor 10.2
38 leukemia, b-cell, chronic 10.2
39 leukemia, acute lymphoblastic 3 10.2 ETV6 FLT3 RUNX1
40 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.2 JAK2 PDGFRB
41 myofibroma 10.2 ETV6 PDGFRB
42 primary polycythemia 10.2 ASXL1 JAK2 TET2
43 sarcoma 10.2
44 dermatitis 10.2
45 purpura 10.2
46 histiocytosis 10.2
47 vasculitis 10.2
48 sm-ahnmd 10.2 ASXL1 KIT TET2
49 acute myeloblastic leukemia with maturation 10.2 FLT3 KIT
50 acute erythroid leukemia 10.2 GATA2 JAK2

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia
Sources

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

About this section

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fever, fatigue, night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

27 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.08 EZH2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.08 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.08 EZH2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.08 CSF1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.08 PTPN11
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.08 PTPN11
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.08 SETBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.08 CSF2 PTPN11
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.08 SETBP1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.08 CSF1 PTPN11
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.08 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.08 KIT SETBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.08 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.08 SETBP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.08 CSF1 CSF2 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.08 PTPN11
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.08 SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.08 CSF2 EZH2 PTPN11 SETBP1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.08 SETBP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.08 CSF1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.08 CSF2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.08 EZH2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.08 EZH2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.08 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.08 EZH2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.08 PTPN11
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.08 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.08 CSF1 PTPN11
29 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.08 CSF2 EZH2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.08 PTPN11
31 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.08 EZH2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.08 EZH2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.08 PTPN11
34 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.08 SETBP1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.08 SETBP1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.08 EZH2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.08 KIT SETBP1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.08 EZH2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.08 KIT
40 Increased shRNA abundance (Z-score > 2) GR00366-A-90 10.08 CSF1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.08 KIT

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

47 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.54 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
2 hematopoietic system MP:0005397 10.49 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
3 growth/size/body region MP:0005378 10.48 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
4 endocrine/exocrine gland MP:0005379 10.46 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
5 homeostasis/metabolism MP:0005376 10.45 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
6 immune system MP:0005387 10.44 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
7 mortality/aging MP:0010768 10.43 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
8 cardiovascular system MP:0005385 10.37 CSF1 CSF2 ETV6 EZH2 GATA2 KDM6A
9 embryo MP:0005380 10.35 CSF2 DNMT3A ETV6 EZH2 GATA2 JAK2
10 behavior/neurological MP:0005386 10.34 ASXL1 CSF1 CSF2 DNMT3A EZH2 HIP1
11 neoplasm MP:0002006 10.22 ASXL1 CSF2 ETV6 EZH2 FLT3 HIP1
12 integument MP:0010771 10.19 CSF1 CSF2 ETV6 EZH2 JAK2 KIT
13 craniofacial MP:0005382 10.18 ASXL1 CSF1 CSF2 KDM6A KIT NF1
14 liver/biliary system MP:0005370 10.18 ASXL1 CSF1 GATA2 HIP1 JAK2 KIT
15 nervous system MP:0003631 10.15 CSF1 CSF2 DNMT3A EZH2 GATA2 HIP1
16 muscle MP:0005369 10.09 CSF1 DNMT3A EZH2 HIP1 KDM6A KIT
17 normal MP:0002873 10.03 ETV6 EZH2 GATA2 HIP1 JAK2 KDM6A
18 no phenotypic analysis MP:0003012 9.97 CSF1 ETV6 EZH2 FLT3 KDM6A KIT
19 reproductive system MP:0005389 9.85 CSF1 CSF2 DNMT3A GATA2 HIP1 JAK2
20 respiratory system MP:0005388 9.56 CSF1 CSF2 HIP1 KDM6A KIT NF1
21 skeleton MP:0005390 9.44 ASXL1 CSF1 CSF2 EZH2 FLT3 HIP1
Sources

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

About this section

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 441)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
3 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
9
Mercaptopurine Approved Phase 3 50-44-2 667490
10
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
11
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
15
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
16
Idarubicin Approved Phase 3,Phase 1,Phase 2,Not Applicable 58957-92-9 42890
17
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
18
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
19
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
20
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
21
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
22
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 50-24-8 5755
23
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 302-25-0
24
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 83-43-2 6741
25
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 1,Not Applicable 2921-57-5
26
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
27
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
28
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
29
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
30
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
31
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
32
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
34
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
35
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 1177-87-3
37
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
38
Thioguanine Approved Phase 3 154-42-7 2723601
39
Acyclovir Approved Phase 3 59277-89-3 2022
40
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
41
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Dalteparin Approved Phase 3 9005-49-6
44
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 46507594 772
45
Ondansetron Approved Phase 3,Phase 2,Phase 1,Not Applicable 99614-02-5 4595
46
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
47
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
48
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
49
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
50
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 508)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
14 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
17 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
18 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
19 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
25 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
32 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
33 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
34 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
35 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
36 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
37 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
38 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
39 Study of ASTX727 vs IV Decitabine in MDS and CMML Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
40 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
41 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
42 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
43 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
44 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
45 Azacytidine + HAG Regimen in Elderly Patients With Myeloid Malignancy. Not yet recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
46 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
47 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
48 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
49 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
50 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Sources

Genetic Tests for Chronic Myelomonocytic Leukemia

About this section

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 30
Sources

Anatomical Context for Chronic Myelomonocytic Leukemia

About this section

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

42
Myeloid, Bone, Bone Marrow, T Cells, Monocytes, Kidney, Liver
Sources

Publications for Chronic Myelomonocytic Leukemia

About this section

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 663)
# Title Authors Year
1
Massive Hemoptysis Due to the Rupture of Thoracic Aortic Aneurysm Caused by Leukemic Cell Infiltration in a Patient With Chronic Myelomonocytic Leukemia. ( 30701008 )
2019
2
Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. ( 30635983 )
2019
3
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. ( 29982850 )
2019
4
Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis? ( 30182347 )
2019
5
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. ( 30328139 )
2019
6
Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. ( 30447300 )
2019
7
Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. ( 30606787 )
2019
8
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. ( 30613922 )
2019
9
Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. ( 30690330 )
2019
10
GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. ( 30710465 )
2019
11
Update on the pathologic diagnosis of chronic myelomonocytic leukemia. ( 30723295 )
2019
12
Molecular Cytogenetic Characterization of a Case of a Myelodysplastic/Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia-1 (CMML-1) with Abnormal Karyotype with an Apparent Monosomy 7 Resulting in Rearrangements Involving Chromosomes 7 and 21. ( 30840601 )
2019
13
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. ( 30894665 )
2019
14
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. ( 30898482 )
2019
15
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. ( 30923049 )
2019
16
NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. ( 30944097 )
2019
17
Chronic myelomonocytic leukemia as a transformation from polycythemia vera. ( 30949429 )
2019
18
Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia. ( 30958078 )
2019
19
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. ( 30964202 )
2019
20
A case of palisaded neutrophilic granulomatous dermatitis with subsequent development of chronic myelomonocytic leukemia. ( 30997066 )
2019
21
Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. ( 31007140 )
2019
22
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. ( 31048357 )
2019
23
TUMOR LYSIS SYNDROME DUE TO TARGETING OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH CHRONIC MYELOMONOCYTIC LEUKEMIA ( 31067853 )
2019
24
Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. ( 31093889 )
2019
25
Chronic myelomonocytic leukemia-related vasculitis mimicking giant cell arteritis. ( 31109503 )
2019
26
Palisaded neutrophilic and granulomatous dermatitis in a patient with chronic myelomonocytic leukemia. ( 30773700 )
2019
27
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. ( 30190511 )
2018
28
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
29
Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. ( 29368535 )
2018
30
Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. ( 29475821 )
2018
31
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. ( 29557496 )
2018
32
Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia. ( 29568655 )
2018
33
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. ( 29582697 )
2018
34
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. ( 29588547 )
2018
35
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. ( 29596070 )
2018
36
CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia. ( 29600428 )
2018
37
Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature. ( 29658352 )
2018
38
Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia. ( 29687069 )
2018
39
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. ( 29707521 )
2018
40
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. ( 29712989 )
2018
41
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. ( 29728305 )
2018
42
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
43
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. ( 29749401 )
2018
44
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. ( 29757120 )
2018
45
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. ( 29775844 )
2018
46
The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia. ( 29797820 )
2018
47
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. ( 29878489 )
2018
48
Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms. ( 29891120 )
2018
49
Characterization of chronic myelomonocytic leukemia with TP53 mutations. ( 29908419 )
2018
50
So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology. ( 29955129 )
2018
Sources

Variations for Chronic Myelomonocytic Leukemia

About this section

ClinVar genetic disease variations for Chronic Myelomonocytic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6; FLT3 t(12;13)(p13.2;q12.2) Translocation Likely pathogenic GRCh37 Chromosome 12, 12037520: 12037521
2 ETV6; FLT3 t(12;13)(p13.2;q12.2) Translocation Likely pathogenic GRCh37 Chromosome 13, 28608350: 28608351

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia
Sources

Expression for Chronic Myelomonocytic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.
Sources

Pathways for Chronic Myelomonocytic Leukemia

About this section

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 67
Show member pathways
 13.37 CSF2 EZH2 JAK2 KDM6A KIT NF1
2
Akt Signaling 65
Show member pathways
 13.31 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
3
PAK Pathway 65
Show member pathways
 13.18 CSF1 CSF2 CSF3R JAK2 KIT PDGFRB
4
Cytokine Signaling in Immune system 67
Show member pathways
 13.02 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
5
PI3K-Akt signaling pathway 38
Show member pathways
 12.85 CSF1 CSF3R FLT3 JAK2 KIT PDGFRB
6
Endometrial cancer 38
Show member pathways
 12.72 CSF2 FLT3 KIT PDGFRB PTPN11 RUNX1
7
Pathways in cancer 38
12.66 CSF3R FLT3 JAK2 KIT PDGFRB RUNX1
8
MAPK signaling pathway 1 38
12.65 CSF1 FLT3 KIT NF1 PDGFRB
9
Ras signaling pathway 38
Show member pathways
 12.55 CSF1 FLT3 KIT NF1 PDGFRB PTPN11
10
Chromatin Regulation / Acetylation 4
12.31 DNMT3A EZH2 KDM6A TET2
11
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.24 CSF2 CSF3R JAK2 PDGFRB PTPN11
12
Transcriptional misregulation in cancer 38
11.99 CSF2 ETV6 FLT3 KDM6A RUNX1
13
Tyrosine Kinases / Adaptors 4
11.98 FLT3 JAK2 KIT PDGFRB
14
VEGF Pathway (Tocris) 62
Show member pathways
 11.69 FLT3 KIT PDGFRB
15
Central carbon metabolism in cancer 38
11.56 FLT3 KIT PDGFRB
16
Dendritic Cells Developmental Lineage Pathway 66
11.54 CSF1 CSF2 FLT3 KIT
17
MECP2 and Associated Rett Syndrome 1
11.52 EZH2 NF1 TET2
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.42 CSF1 CSF2 CSF3R FLT3 KIT
19
Signaling events mediated by PTP1B 1
11.4 CSF1 JAK2 PDGFRB
20
Hematopoietic Stem Cell Differentiation 1
11.14 CSF1 CSF2 GATA2 RUNX1
21
Hematopoietic cell lineage 38
11.01 CSF1 CSF2 CSF3R FLT3 KIT
22
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.92 DNMT3A ETV6 FLT3
23
G-protein signaling_Rap2B regulation pathway 23
10.91 CSF1 CSF2 FLT3 KIT PDGFRB
24
Development of pulmonary dendritic cells and macrophage subsets 1
10.72 CSF1 CSF2
Sources

GO Terms for Chronic Myelomonocytic Leukemia

About this section

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.53 ASXL1 DNMT3A ETV6 EZH2 FLT3 GATA2
2 receptor complex GO:0043235 9.26 CSF3R FLT3 KIT PDGFRB

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.97 CSF1 ETV6 FLT3 GATA2 HIP1 JAK2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 FLT3 KIT PDGFRB PTPN11
3 positive regulation of cell migration GO:0030335 9.91 CSF1 JAK2 KIT PDGFRB
4 regulation of gene expression GO:0010468 9.91 CSF2 DNMT3A EZH2 KDM6A NF1
5 chromatin organization GO:0006325 9.91 ASXL1 DNMT3A EZH2 JAK2 KDM6A TET2
6 regulation of cell proliferation GO:0042127 9.88 CSF2 EZH2 KIT NF1
7 protein autophosphorylation GO:0046777 9.88 FLT3 JAK2 KIT PDGFRB
8 positive regulation of protein kinase B signaling GO:0051897 9.87 HIP1 KIT PDGFRB PTPN11
9 positive regulation of cell proliferation GO:0008284 9.87 CSF1 CSF2 EZH2 FLT3 JAK2 KIT
10 response to estradiol GO:0032355 9.83 DNMT3A EZH2 PDGFRB
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 CSF1 FLT3 KIT PDGFRB
12 heart development GO:0007507 9.79 KDM6A NF1 PTPN11
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 FLT3 JAK2 KIT PDGFRB
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 CSF2 FLT3 JAK2 KIT
15 homeostasis of number of cells within a tissue GO:0048873 9.73 CSF1 GATA2 PTPN11
16 platelet-derived growth factor receptor signaling pathway GO:0048008 9.72 JAK2 PDGFRB PTPN11
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 FLT3 KIT PDGFRB
18 peptidyl-tyrosine phosphorylation GO:0018108 9.71 FLT3 JAK2 KIT PDGFRB
19 positive regulation of MAP kinase activity GO:0043406 9.67 EZH2 FLT3 KIT PDGFRB
20 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.66 CSF1 CSF2
21 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.65 JAK2 PDGFRB
22 interleukin-6-mediated signaling pathway GO:0070102 9.65 JAK2 PTPN11
23 megakaryocyte development GO:0035855 9.64 KIT PTPN11
24 hematopoietic stem cell proliferation GO:0071425 9.64 ETV6 RUNX1
25 positive regulation of phospholipase C activity GO:0010863 9.63 KIT PDGFRB
26 dendritic cell differentiation GO:0097028 9.63 CSF2 FLT3
27 MAPK cascade GO:0000165 9.63 CSF2 FLT3 JAK2 KIT NF1 PDGFRB
28 response to fluid shear stress GO:0034405 9.61 CSF2 PDGFRB
29 myeloid progenitor cell differentiation GO:0002318 9.59 FLT3 KIT
30 cytokine-mediated signaling pathway GO:0019221 9.5 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
31 regulation of myeloid cell differentiation GO:0045637 9.43 CSF2 CSF3R RUNX1
32 hemopoiesis GO:0030097 9.1 ASXL1 CSF1 FLT3 GATA2 KIT RUNX1
33 positive regulation of gene expression GO:0010628 10 CSF1 CSF2 GATA2 KDM6A KIT

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.72 ASXL1 DNMT3A EZH2 GATA2 KDM6A
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.63 DNMT3A ETV6 EZH2 GATA2 KDM6A RUNX1
3 protein binding GO:0005515 9.6 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FLT3 KIT PDGFRB
5 insulin receptor substrate binding GO:0043560 9.4 JAK2 PTPN11
6 peptide hormone receptor binding GO:0051428 9.37 JAK2 PTPN11
7 protein tyrosine kinase activity GO:0004713 9.26 FLT3 JAK2 KIT PDGFRB
Sources

Sources for Chronic Myelomonocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....